Sequence analysis of 131 human brains has revealed the mutagenesis processes that take place throughout life, from development to senescence. In a new study published in the July 29, 2022, issue of Science, the authors described how high rates of brain somatic mutations (what they call hypermutability) correlated with age.
Top-line results from Vistagen Therapeutics Inc.’s Palisade-1 phase III study of PH-94B for treating social anxiety disorder showed the therapy fell shy of the primary endpoint. The South San Francisco-based company’s stock (NASDAQ:VTGN) fell dramatically on the results July 22 as shares closed 86% lower at 15 cents each.
As neurological disease stocks begin to move in the right direction, and a potential U.S. FDA approval nears for a major depressive disease drug, shares are still down by 11.68% this year. BioWorld’s Neurological Diseases Index is following a similar path as the Nasdaq Biotechnology Index (NBI), which hit bottom at the end of May and has begun to climb since then. Still, NBI is down 15.92% this year, while the Dow Jones Industrial Average is down 12.41%.
The U.K.’s competition watchdog has found that a subsidiary of Pfizer Inc. and a generics firm jacked up the price of a life-saving epilepsy drug by up to 2,600%, fining them a total of £70 million (US$83.72 million). The Competition and Markets Authority’s decision is part of a long-running dispute against subsidiary Pfizer Ltd. and the generics firm Flynn Pharma Ltd.
In a sense, memories are useless without being linked to feelings. Without knowing whether a memory is good or bad, there is no way to seek out good experiences, and avoid bad ones. Now, investigators at the Salk Institute have identified neurotensin as a critical molecule for the assignment of such emotional valence.
Japan’s Kyowa Kirin Co. Ltd. has stopped development of its adenosine A2a receptor antagonist, KW-6356, in Parkinson’s disease. Discovered internally by Kyowa Kirin, KW-6356 was studied in phase II trials in Japan for Parkinson’s disease, with results showing it was “potentially effective in relieving motor and non-motor symptoms both as a monotherapy and in combination with levodopa-containing therapy,” Kyowa said. However, development is now being discontinued after conducting an evaluation of the global regulatory landscape, development hurdles and potential timelines for market entry.
New interim data from Ultragenyx Pharmaceutical Inc. and Genetx Biotherapeutics LLC’s phase I/II study of GTX-102 in Angelman’s syndrome didn’t do much to bolster investor confidence, as Ultragenyx shares sagged considerably July 19. The Novato, Calif.-based company’s stock (NADAQ:RARE) closed 13% downward at $52.89 per share. That is nearly half the price shares fetched in late August. At $102.40 per share, that was the stock’s highest value in the past 12 months.
Three serious adverse events have led the U.S. FDA to place a clinical hold on Diamedica Therapeutics Inc.’s phase II/III study of DM-199, a synthetic form of human tissue kallikrein-1 for treating acute ischemic stroke. The blood pressure in three participants dropped to a significantly low level shortly after receiving an I.V. dose of the therapy. All three bounced back to normal within minutes of stopping the I.V.
After filing patents on a decades-old antipsychotic, Aneurotech BV is laying plans for a U.S. phase IIIb trial of the drug as an adjunctive therapy in major depressive disorder. The study will assess the effects of ANT-01, a low dose of pipamperone, a selective antagonist of both the serotonin 5-HT2A and D4 dopamine receptors, which has been on the market in some countries in Europe and elsewhere for more than 40 years.
New and updated preclinical and clinical data presented by biopharma firms at the European Academy of Neurology Congress, including: Bristol Myers Squibb, Horizon, Teva.
RSS
